Status:
UNKNOWN
Levamisole and Isoprinosine in the Treatment of COVID19: A Proposed Therapeutic Trial
Lead Sponsor:
Cairo University
Conditions:
Respiratory Tract Infections
Eligibility:
All Genders
6-90 years
Phase:
PHASE3
Brief Summary
The use of both levamisole \& Isoprinosine has both synergistic and complementary effect in the treatment of COVID 19 infection
Detailed Description
Study design: Randomized controlled trial, randomization by closed envelope technique Informed consent will be written for each patient of either group At the beginning of the study all patients will...
Eligibility Criteria
Inclusion
- Confirmed COVID 19 infection (positive PCR, elevated ESR, leucopenia)
- Clinical picture of COVID 19 infection including fever, malaise, sore throat, coughing, dyspnea, and runny nose
Exclusion
- Mild cases of COVID 19 that do not require hospitalization
- Pregnant \& lactating women
- Children with other comorbidities
- People who received previous treatment for COVID 19 in the last 2 weeks N.B. Diabetes and hypertension not excluded
Key Trial Info
Start Date :
May 5 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 30 2020
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04383717
Start Date
May 5 2020
End Date
October 30 2020
Last Update
May 13 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.